Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
暂无分享,去创建一个
Š. Pospíšilová | J. Fajkus | K. Černá | J. Novotná | M. Fojtová | G. Pavlasová | J. Oppelt | M. Mraz | M. Doubek | J. Mayer | Y. Brychtova | M. Borsky | Vaclav Seda | V. Svobodová | V. Seda